BABASAKI, Takashi

論文

  1. Kobayashi G, Sentani K, Babasaki T, Sekino Y, Shigematsu Y, Hayashi T, Oue N, Teishima J, Matsubara A, Sasaki N, Yasui W.
    Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.
    Cancer Sci. 2020 Jan 7. doi: 10.1111/cas.14299. [Epub ahead of print]
    Abstract:パブメドGoogle ScholarIF:
  2. Han X, Sekino Y, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A.
    Microtubule-associated Protein Tau (MAPT) is a promising independent prognostic marker and tumor suppressive protein in clear cell renal cell carcinoma.
    Urol Oncol. 2020 Mar 2. pii: S1078-1439(20)30051-X.
    Abstract:パブメドGoogle ScholarIF:
  3. Yamanaka R, Sekino Y, Babasaki T, Kitano H, Ikeda K, Goto K, Hieda K, Inoue S, Hayashi T, Teishima J, Aikata H, Chayama K, Sentani K, Yasui W, Matsubara A.
    Renal Metastasis from Primary Hepatocellular Carcinoma: A case report.
    Int Cancer Conf J, Mar 25, 2020, Epub.
    Abstract:パブメドGoogle ScholarIF:
  4. Sekino Y, Hagura T, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shigeta M, Taniyama D, Kuraoka K, Sentani K, Yasui W,Matsubara A.
    PTEN is involved in sunitinib and sorafenib resistance in renal cell carcinoma.
    Anticancer Res 40:1943-1951, 2020.
    Abstract:パブメドGoogle ScholarIF:
  5. Sekino Y, Han X, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Takeshima Y, Yasui W, Matsubara A.
    Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
    Urol Oncol. 2020 May 16: S1078-1439(20): 30191-30195, 2020.
    Abstract:パブメドGoogle ScholarIF:
  6. Sekino Y, Han X, Babasaki T, Miyamoto S, Kitano H, Kobayashi G, Goto K, Inoue S, Hayashi T, Teishima J, Sakamoto N, Sentani K, Oue N, Yasui W, Matsubara A.
    TUBB3 is associated with high-grade histology, poor prognosis, p53 expression, and cancer stem cell markers in clear cell renal cell carcinoma.
    Oncology, in press.
    Abstract:パブメドGoogle ScholarIF:
  7. Sekino Y, Han X, Kawaguchi T, Babasaki T, Goto K, Inoue S, Hayashi T, Teishima J, Shiota M, Yasui W, Matsubara A.
    TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
    Int J Mol Sci. 2019 Aug 13;20(16). pii: E3936. doi: 10.3390/ijms20163936.
    Abstract:パブメドGoogle ScholarIF:
  8. 郷力昭宏, 馬場崎 隆志, 小畠浩平, 重松慶紀, 関野陽平, 北野弘之, 後藤景介, 永松弘孝, 稗田圭介, 正路晃一, 井上省吾, 梶原 充, 亭島 淳, 松原昭郎.ハイリスク前立腺癌における術後PSA再発の予測因子. 泌尿器外科. 2015, 28(8), 1345-1347.
  9. 馬場崎隆志、井上省吾、小畠浩平、重松慶紀、関野陽平、北野弘之、永松弘孝、稗田圭介、郷力昭宏、正路晃一、林 哲太郎、梶原 充、亭島 淳、松原昭郎.低強度体外衝撃波によるED治療効果の検討-陰茎プレチスモグラフィを用いた客観的評価. 西日本泌尿器科2016, 78:330-337.

受賞

2019年 第108回日本病理学会総会 ポスター優秀演題賞